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Objective. To determine linezolid concentrations in peritoneal dialysis fluid
after multiple oral doses of the drug in a 46-year-old man with
vancomycin-resistant Enterococcus faecium peritonitis who was undergoing
peritoneal dialysis.
Methods. After administration of oral linezolid 600 mg twice/day was started,
peritoneal dialysis fluid was collected at the end of several 4- and 8-hour
dwell times and submitted for analysis of linezolid concentration.  Before
linezolid therapy was begun, and immediately after several peritoneal
dialysis exchanges, 30 ml of expended peritoneal dialysis fluid was
collected in a sterile container and immediately frozen at -70ºC until
analysis by high-performance liquid chromatography.
Results. Peritoneal dialysis concentrations of linezolid greater than 4 µg/ml
were achieved after the first dose of linezolid and maintained after repeated
doses.  During the course of therapy, mean linezolid concentrations in
peritoneal dialysis fluid tended to increase (mean 7.60 µg/ml, range
3.54–16.2 µg/ml).  All assayed peritoneal dialysis samples demonstrated
linezolid concentrations greater than 4 µg/ml at the end of 4- or 8-hour
dwell times, except for one level after a missed dose on linezolid treatment
day 3.  Duration of dwell times did not appear to correlate with linezolid
concentrations.
Conclusion. In this patient, linezolid 600 mg twice/day penetrated into
peritoneal dialysis fluid at or above the concentrations necessary to treat
common gram-positive bacteria.  Linezolid therapy is likely to have a role
in peritoneal dialysis–associated peritonitis based on its antimicrobial
activity, pharmacokinetic properties, ease of administration, and tolerability.
(Pharmacotherapy 2003;23(10):1322–1326)
Linezolid, the first commercially available
oxazolidinone antibacterial, demonstrates in vitro
activity against a variety of gram-positive
organisms, such as methicillin-resistant staphylo-
cocci, penicillin-resistant pneumococci, and
vancomycin-resistant Enterococcus faecalis and E.
faecium (VREF).  Recently, linezolid has demon-
strated in vitro activity against glycopeptide-
intermediate1 and vancomycin-resistant Staphylo-
coccus aureus.2, 3 With the emergence of resistant
gram-positive pathogens, linezolid becomes an
increasingly important therapeutic option.
In the past year, our institution experienced an
increased number of infections caused by
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vancomycin-resistant Enterococcus and
Staphylococcus species, requiring treatment with
linezolid.  Several patients developed infections
while receiving peritoneal dialysis.  Linezolid is a
viable treatment option for infections associated
with peritoneal dialysis because the most
important complication of this treatment is
infection of the peritoneal cavity or the catheter
exit site.  This infection usually is caused by
gram-positive organisms.4
Although dosing recommendations for
linezolid in patients undergoing peritoneal
dialysis have not been published, some
pharmacokinetic data for patients with impaired
renal function are available.5 The pharmaco-
kinetics of the parent drug are not altered in
patients with any degree of renal insufficiency.6
Similar plasma concentrations of linezolid are
achieved regardless of renal function; thus, no
dosage adjustment is recommended for patients
with renal insufficiency.6 During intermittent
hemodialysis, linezolid clearance is increased by
approximately 80%.6 Because about 30% of a
600-mg dose of linezolid is removed during a 3-
hour hemodialysis session, current recommen-
dations suggest that linezolid be administered
after hemodialysis is completed.6 However, few
data are available regarding the effect of
peritoneal dialysis on the pharmacokinetics of
linezolid or penetration of linezolid into
peritoneal dialysis fluid.  Inappropriate dosing
could result in subtherapeutic drug concentrations
and therapeutic failure.
To our knowledge, this is the first report of
linezolid concentrations measured in several
samples of peritoneal dialysis fluid obtained after
oral administration of the drug in a patient with
VREF peritonitis who was undergoing peritoneal
dialysis.  Quinupristin-dalfopristin was a
treatment option for our patient, since a few
published case reports indicated its success in
patients with gram-positive peritonitis7, 8;
however, we chose linezolid based on its
antimicrobial activity, pharmacokinetic properties,
ease of administration, and tolerability.
Case Report
A 46-year-old man was admitted to the
University of Michigan Health System with a
chief complaint of chest pain.  He had a history
of coronary artery disease, cerebral vascular
accident, bilateral lower extremity ulcers, and
end-stage renal disease, secondary to diabetes,
that required peritoneal dialysis.  On admission,
his blood urea nitrogen and creatinine levels were
100 and 10 mg/dl, respectively.  He had been
noncompliant with his peritoneal dialysis therapy
and subsequently was transferred to the
nephrology service for peritoneal dialysis and
monitoring.
On day 2 of his hospital stay, the patient
experienced fever up to 101.2°F and acute
changes in mental status.  Chest radiography was
performed, and blood, urine, and peritoneal
dialysis fluid were obtained for culture.  Empiric
therapy with intravenous vancomycin and
piperacillin-tazobactam was begun.  The chest
radiograph was inconsistent with pneumonia,
and all cultures were negative except for blood
cultures drawn from the patient’s indwelling
central catheter, which grew methicillin-resistant
Staphylococcus epidermidis.  After removal of the
catheter, culture of the tip also revealed methi-
cillin-resistant S. epidermis.  The piperacillin-
tazobactam was discontinued; the patient
continued receiving only the intravenous
vancomycin.
The patient’s mental status improved initially,
but his fever continued as high as 102.5ºF over
the next few days despite two sets of negative
blood cultures.  On hospital day 9, intravenous
gentamicin was added to his treatment regimen
for gram-negative coverage.  A transesophageal
echocardiogram revealed a large superior vena
cava thrombus at the site of the removed
catheter.  The patient’s fever continued as high as
102.7ºF over the next week despite therapy with
intravenous vancomycin and gentamicin.
Repeated blood and urine cultures and a chest
radiograph were negative.  On day 21, a culture
of peritoneal dialysis fluid grew Pseudomonas
stutzeri, and the patient’s antibiotic therapy was
changed to intravenous piperacillin and
vancomycin, and intraperitoneal gentamicin.
On hospital day 32, after a peritoneal dialysis
fluid culture revealed the presence of VREF,
antimicrobial therapy was changed to oral
linezolid 600 mg every 12 hours (in addition to
the intraperitoneal gentamicin).  The patient
responded clinically and remained afebrile for the
duration of antibiotic therapy.  Four subsequent
peritoneal dialysis fluid cultures and three sets of
blood cultures were negative.  The patient had no
other clinical signs or symptoms of infection and
was discharged to a nursing home on day 46,
after completing a 2-week course of therapy with
intraperitoneal gentamicin and oral linezolid.
Linezolid therapy was well tolerated, with no
clinical evidence of adverse events.
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Throughout the patient’s linezolid treatment,
peritoneal dialysis was continued, with five daily
cycles consisting of four 4-hour dwell times and
an overnight 8-hour dwell time of standard
peritoneal dialysate of 1.5% dextrose with 2-L
bag exchanges.
Methods
Just before linezolid therapy was begun and
immediately after several peritoneal dialysis
exchanges, 30 ml of expended peritoneal dialysis
fluid from the patient was collected in a sterile
container and immediately frozen at -70ºC until
analysis by high-performance liquid chromato-
graphy (HPLC) assay.9 The system consisted of
an HPLC pump (Model 515, Waters, Milford,
MA) with a gradient controller (Model 680,
Waters) and a solvent select valve, a fixed-
volume autosampler (Model 8875, Spectra
Physics, San Jose, CA), an ultraviolet detector
(Model 486, Waters), a computer (Macintosh
7100, Apple Computers Inc., Cupertino, CA),
and an HPLC data management system
(Dynamax, Rainin, Woburn, MA).
The standard curve for linezolid ranged from
0.5–30 µg/ml.  Absolute recovery of linezolid was
95%.  The within-sample precision (percent
coefficient of variation) of validation for a single
standard concentration was 0.69%; overall
validation precision across all standards was
1.04–4.39%.
Collection and analysis of the peritoneal
dialysis fluid were conducted in accordance with
human subject research guidelines and policies
set forth by the University of Michigan Health
System institutional review board.
Results
After administration of oral linezolid 600 mg
twice/day was started, peritoneal dialysis fluid
was collected at the end of several 4- and 8-hour
dwell times and submitted for analysis of
linezolid concentration (Figure 1).  Peritoneal
dialysis fluid concentrations of linezolid above 4
µg/ml were achieved after the first dose of
linezolid and were maintained after multiple
doses.  Of note, the patient did not receive the
scheduled fourth dose of linezolid due to an
unintentional administration error, which is
reflected by the transient decrease in linezolid
concentrations in the peritoneal dialysis fluid on
linezolid treatment day 3.
Despite the missed dose, the linezolid
concentration in the patient’s peritoneal dialysis
fluid was 3.54 µg/ml 19 hours after adminis-
tration of the third dose.  During the course of
therapy, mean linezolid concentrations in
peritoneal dialysis fluid tended to increase (mean
7.60 µg/ml, range 3.54–16.2 µg/ml).  Duration of
dwell times did not appear to correlate with
linezolid concentrations in peritoneal dialysis
fluid.  Plasma samples were not obtained for
linezolid analysis.
Discussion
Linezolid is bacteriostatic against most
susceptible organisms but displays bactericidal
activity against some strains of pneumococci.10
The breakpoint concentration for linezolid-
susceptible enterococci and streptococci is a
minimum inhibitory concentration (MIC) of 2
µg/ml or below, and for susceptible staphylococci
4 µg/ml or below.  Breakpoints for other gram-
positive pathogens have not been established.5
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Figure 1. Peritoneal dialysis fluid concentrations of
linezolid in a patient receiving multiple oral doses of oral
linezolid 600 mg every 12 hours for treatment of peritonitis.
Peritoneal dialysis fluid cultures yielded vancomycin-
resistant Enterococcus faecium.  Linezolid administration
times were 12 P.M. and 12 A.M..  The patient was scheduled
to receive dialysis in cycles of four 4-hour and one 8-hour
dwell times/day.  However, each dwell time actually differed
slightly due to interruptions throughout the day (e.g.,
patient out of his room for a procedure).  In addition, the
patient did not receive the scheduled fourth dose of
linezolid (arrow), which is reflected by the transient
decrease in linezolid concentrations in his peritoneal
dialysis fluid on treatment day 3.  ++++ indicates the
breakpoint concentrations for susceptible staphylococci to
linezolid (minimum inhibitory concentration [MIC] ≤ 4
µg/ml); – – – indicates breakpoint concentrations for
susceptible enterococci and streptococci to linezolid (MIC ≤
2 µg/ml).
PERITONEAL DIALYSIS FLUID CONCENTRATIONS OF LINEZOLID  DePestel et al
Linezolid exhibits rapid and complete
absorption after oral administration to healthy
subjects; peak plasma concentrations are
achieved within 1–2 hours, and mean oral
bioavailability is approximately 100%, whether or
not the drug is administered with meals.5
Therefore, administration of linezolid may be
oral or intravenous.  In healthy subjects, steady-
state peak and trough serum concentrations of
21.20 ± 5.78 and 6.15 ± 2.94 µg/ml, respectively,
are achieved after oral linezolid 600 mg
twice/day, with an elimination half-life is 4.5–5.5
hours.5 Linezolid has a steady-state volume of
distribution of 40–50 L and is 31% bound to
plasma protein.5
Linezolid undergoes hepatic oxidation to
metabolites with minimal or no antimicrobial
activity.  Its metabolism does not involve
cytochrome P450 (CYP) and does not inhibit or
induce any clinically significant CYP isoforms,
such as 1A2, 2C9, 2C19, 2D6, 2E1, or 3A4.  The
parent drug and its metabolites are primarily
cleared by renal excretion; approximately 30% of
the dose excreted is unchanged in urine.5 The
recommended linezolid dosage for adult patients
with infection caused by susceptible gram-
positive pathogens is 600 mg every 12 hours.
The main reason we obtained these linezolid
concentrations in peritoneal dialysis fluid was to
ensure that our patient had therapeutic linezolid
concentrations at the site of infection.  Animal
data suggest that the major pharmacodynamic
parameter determining efficacy for linezolid is
the amount of time the drug concentration
remains above the MIC of the pathogen.11
Therefore, drug concentrations at the site of
infection should be maintained at or above the
MIC for most of the dosing interval.  In our
patient, administration of oral linezolid 600 mg
twice/day produced peritoneal dialysis fluid
concentrations consistently above 4 µg/ml at the
end of 4- and 8-hour dwell times, except for one
instance after inadvertent omission of the
patient’s fourth dose.
Animal and human pharmacokinetic data have
demonstrated that linezolid readily distributes
into well-perfused tissues.5 The pharmacokinetic
properties of linezolid, such as a large volume of
distribution and low protein binding, suggest
that the drug should distribute well into tissues
and aqueous fluid, such as peritoneal dialysis
fluid.  Data from a few healthy volunteers have
suggested sufficient penetration of drug into a
variety of sites, such as skin blister and
pancreatic abscess fluids as well as pulmonary
and osteoarticular tissues.12–15 Linezolid appears
to penetrate into these tissues at or above the
concentrations necessary to treat common gram-
positive bacteria (MIC ‡ 4 µg/ml).
One study investigated the penetration of
linezolid into peritoneal dialysis fluid in seven
patients who exhibited no evidence of peritonitis
and were undergoing continuous ambulatory or
continuous cycling peritoneal dialysis.16 Patients
were given a single dose of linezolid 600 mg
immediately after an exchange of 2 L of 2.5%
dextrose solution.  Linezolid concentrations in
serum and peritoneal dialysis fluid were
measured hourly for 6 hours and at 24 hours
after the dose.  The combined data for both types
of dialysis provided a peritoneal dialysate:plasma
ratio of 0.69 for the area under the curve.
Concentrations of linezolid in peritoneal dialysis
fluid were maintained at above 2 µg/ml for an
average of 22 hours after the single dose.
Another study reported the first case of
peritoneal dialysis–associated VREF peritonitis
treated with linezolid.17 A loading dose of 1200
mg administered by nasogastric tube was
followed by a maintenance dosage of intravenous
linezolid 600 mg every 12 hours.  In a single
sample of peritoneal dialysis fluid obtained 20.5
hours after the loading dose, linezolid
concentration was 7.14 µg/ml.  Concomitant
plasma samples were not obtained.
Conclusion
To our knowledge, this is the first report of
linezolid concentrations measured in peritoneal
dialysis fluid after multiple doses of oral linezolid
600 mg twice/day in a patient with VREF
peritonitis who was undergoing peritoneal
dialysis.  Several samples of peritoneal dialysis
fluid were obtained during therapy and analyzed
to determine linezolid concentrations.  Our data
suggest that linezolid 600 mg twice/day
penetrates into peritoneal dialysis fluid at or
above the concentrations necessary to treat
common gram-positive bacteria.  Linezolid
therapy is likely to have a role in peritoneal
dialysis–associated peritonitis based on its
antimicrobial activity, pharmacokinetic properties,
ease of administration, and tolerability.  No data
have yet been published regarding treatment of
peritonitis by intraperitoneal administration of
linezolid.  Further clinical studies are needed to
adequately assess the use of linezolid for
treatment of gram-positive peritonitis.
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